|
Webinar:
Adjuvanted Mucosal Subunit Vaccine for Preventing SARS-CoV-2 Transmission and Infection |
|
 |
Register to attend a free NCI webinar. Attendees will learn about a new adjuvanted subunit mucosal Covid-19 vaccine. Study results show that this new vaccine prevents SARS-CoV-2 transmission and infection. Most SARS-CoV-2 vaccines focus on delivering immunization through an intramuscular injection. This new technology combines an initial intramuscular injection with subsequent intranasal boost administration of a novel, molecular adjuvant nanoparticle formulation.
Competitive Advantages
- Stimulates both systemic and mucosal immunity; induces both humoral and cellular immunity, as well as trained innate immunity.
- Leads to more effective virus clearance from the upper respiratory tract from which it could spread.
- Stimulates sustained immune response.
- Protects against SARS-CoV-2 variants.
- Prevents or reduces onward transmission to others, addressing an important public health need.
- Avoids painful injection with intranasal administration .
- Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.
Commercial Applications:
- Adjuvanted mucosal subunit vaccines (as single agents)
- Vaccine composition(s)
- Co-administration to enhance the effect of systemic immunization.
|
|
Why Attend?
- Assess co-developing the technology.
- Interact with the inventor, ask questions and provide feedback.
- Learn how to partner with the NCI and NIH.
|
Who Should Attend?
- Business development professionals
- Drug development professionals
- Investors and entrepreneurs
- Biotech/pharma/academia researchers
|
|
|
|
|
